Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Holdings in Stryker Corporation (SYK)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 0.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,301,229 shares of the medical technology company’s stock after selling 9,112 shares during the quarter. Stryker comprises about 3.7% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s investment portfolio, making the stock its 2nd biggest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned 0.35% of Stryker worth $201,482,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Davis Rea Ltd. grew its stake in shares of Stryker by 1.1% during the fourth quarter. Davis Rea Ltd. now owns 51,594 shares of the medical technology company’s stock valued at $8,013,000 after buying an additional 543 shares during the last quarter. Global Financial Private Capital LLC grew its stake in shares of Stryker by 17.1% during the fourth quarter. Global Financial Private Capital LLC now owns 20,121 shares of the medical technology company’s stock valued at $3,117,000 after buying an additional 2,942 shares during the last quarter. Toronto Dominion Bank grew its stake in shares of Stryker by 13.8% during the fourth quarter. Toronto Dominion Bank now owns 139,510 shares of the medical technology company’s stock valued at $21,601,000 after buying an additional 16,865 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Stryker by 21.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 800,264 shares of the medical technology company’s stock valued at $123,912,000 after buying an additional 141,952 shares during the last quarter. Finally, Weatherstone Capital Management grew its stake in shares of Stryker by 21.7% during the fourth quarter. Weatherstone Capital Management now owns 2,965 shares of the medical technology company’s stock valued at $459,000 after buying an additional 528 shares during the last quarter. 74.71% of the stock is currently owned by institutional investors.

Shares of Stryker Corporation (NYSE:SYK) opened at $158.54 on Friday. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $58,534.07, a P/E ratio of 24.07, a P/E/G ratio of 2.25 and a beta of 0.70. Stryker Corporation has a twelve month low of $124.89 and a twelve month high of $170.00.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.01. The firm had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.78 earnings per share. research analysts expect that Stryker Corporation will post 7.12 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.19%. Stryker’s dividend payout ratio is currently 70.15%.

A number of research analysts have recently commented on the company. SunTrust Banks reaffirmed a “buy” rating and set a $179.00 target price (up previously from $161.00) on shares of Stryker in a research note on Friday, January 26th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $163.00 target price on shares of Stryker in a research note on Tuesday, January 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research note on Wednesday, January 31st. Leerink Swann upped their target price on Stryker from $177.00 to $184.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Finally, Oppenheimer reaffirmed a “hold” rating and set a $165.00 target price on shares of Stryker in a research note on Thursday, February 1st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $162.50.

In other Stryker news, VP William E. Berry, Jr. sold 1,306 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total transaction of $214,732.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Graham A. Mclean sold 2,984 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $160.53, for a total value of $479,021.52. Following the sale, the insider now owns 9,100 shares of the company’s stock, valued at approximately $1,460,823. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,840 shares of company stock valued at $2,749,989. 7.40% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This piece was published by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://weekherald.com/2018/02/16/loring-wolcott-coolidge-fiduciary-advisors-llp-ma-trims-holdings-in-stryker-corporation-syk.html.

Stryker Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply